The financial information for Intuitive Surgical, Inc. for the period ending September 30, 2023, demonstrates significant increases in assets, revenue, and net income compared to the prior year. The company's operational details include revenue from product and service sales, operating expenses, income from operations, net income figures, and a $5.6 million impairment. Intuitive Surgical engages in hedging programs, utilizing derivatives as cash flow hedges, and reports gains and losses as components of accumulated other comprehensive loss. The balance sheet includes accounts receivable, inventory, prepaids, property, plant, equipment, and accrued liabilities. The report also details revenue breakdown, lease specifics, and potential credit loss risks, while noting the company's proactive strategies in managing supply chain disruptions, inflationary pressures, and other risks.
The company's management discussion and analysis of its financial condition and operations as of September 30, 2023, includes forward-looking statements on future financial outcomes. It highlights the company's mission, technology advancements, strategic initiatives, and commercialization efforts. The text emphasizes the commitment to advancing minimally invasive care through products like the da Vinci surgical systems and Ion endoluminal system, while discussing the potential risks and uncertainties affecting financial performance. Furthermore, the company has obtained various regulatory clearances for its surgical systems like the da Vinci Xi in countries such as the U.S., Japan, and China, expanding its market presence. The impact of regulations in certain regions on pricing and technology usage is addressed, alongside the increase in da Vinci procedures globally, notably in urologic and general surgeries, and the growth of procedures using the Ion system. Overall, the company strives to offer innovative surgical solutions focusing on procedure efficacy and invasiveness through its robotic systems.
There have been no significant changes in the market risk for the company during the three months ending September 30, 2023, when compared to the disclosures made in Part II, Item 7A of their Annual Report on Form 10-K for the year ending December 31, 2022.
The text discusses the evaluation of disclosure controls and procedures maintained by a company to ensure timely and accurate disclosure in Exchange Act reports. The company conducted an evaluation of the effectiveness of these controls, with its management concluding that they were effective at the reasonable assurance level. Additionally, there have been no material changes in the internal control over financial reporting during the most recent fiscal quarter.
The text provided indicates that the information concerning legal proceedings is included in Note 8 of the Condensed Consolidated Financial Statements, which can be found in Part I of the quarterly report being referenced.
The text discusses various risk factors that may affect the business, financial position, or future results of operations of a company, including risks related to macroeconomic conditions, supply chain constraints, reliance on sole-sourced suppliers, operations outside of the U.S., information technology system failures and cybersecurity risks, credit risk, fluctuations in market value of investments, and changes in the effective tax rate. Macroeconomic conditions, cybersecurity incidents, supply chain disruptions, and political tensions such as those between Russia and Ukraine are highlighted as potential threats to the company's operations and financial stability. Additionally, risks related to regulations and trade policies in various jurisdictions, such as the UK and the U.S., are also discussed as factors that could impact the company's business and financial performance. Other risks related to data breaches, cybersecurity incidents, global economic uncertainty, and changes in tax laws are further highlighted as significant concerns that may impact the company's operational efficiency and financial performance.
There were no unregistered sales of equity securities during the period covered by the report. The company's stock repurchase activity for the quarter ended September 30, 2023, totaled $1.1 billion, with $1.1 billion remaining for repurchasing shares under the authorized stock repurchase program as of that date. The company has had an active stock repurchase program since March 2009, and the Board has authorized up to $10.0 billion for stock repurchases, with the most recent authorization being for $3.5 billion in July 2022. The program does not have an expiration date.
The text provided mentions that there are no defaults on senior securities.
The text provided states that there are no mine safety disclosures applicable.
Myriam J. Curet, the Chief Medical Officer of the company, adopted a Rule 10b5-1 trading plan on August 11, 2023. The plan allows for the potential sale of up to 27,077 shares of the company's common stock, including the exercise and sale of up to 21,273 shares of stock options, until August 12, 2024. The trading plan was established during an open insider trading window in compliance with Rule 10b5-1(c) of the Securities Exchange Act of 1934 and the company's securities transaction policies.
The text provides a list of exhibits included in Intuitive Surgical, Inc.'s regulatory filings, detailing certificates, certifications pursuant to the Sarbanes-Oxley Act of 2002, Inline XBRL financial reporting materials, and references to various regulatory filings. The Signature section confirms the report's authorization by the company's Senior Vice President, Jamie E. Samath, the Chief Financial Officer.
